293 related articles for article (PubMed ID: 30609118)
21.
Jung KH; Park JW; Lee JH; Moon SH; Cho YS; Lee KH
J Nucl Med; 2021 May; 62(5):656-664. PubMed ID: 32917780
[TBL] [Abstract][Full Text] [Related]
22. Construction of Anti-hPD-L1 HCAb Nb6 and
Huang HF; Zhu H; Li GH; Xie Q; Yang XT; Xu XX; Tian XB; Wan YK; Yang Z
Bioconjug Chem; 2019 Oct; 30(10):2614-2623. PubMed ID: 31535847
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-93-5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand-1 in colorectal cancer.
Chen YL; Wang GX; Lin BA; Huang JS
Cell Biol Int; 2020 May; 44(5):1224-1236. PubMed ID: 32068322
[TBL] [Abstract][Full Text] [Related]
24. Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model.
Li J; Xu J; Yan X; Jin K; Li W; Zhang R
Med Sci Monit; 2018 Aug; 24():5501-5508. PubMed ID: 30087314
[TBL] [Abstract][Full Text] [Related]
25. Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer.
Wang C; Weng M; Xia S; Zhang M; Chen C; Tang J; Huang D; Yu H; Sun W; Zhang H; Lai M
Cancer Sci; 2021 Jan; 112(1):178-193. PubMed ID: 33058325
[TBL] [Abstract][Full Text] [Related]
26. The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer.
Zhao L; Yu H; Yi S; Peng X; Su P; Xiao Z; Liu R; Tang A; Li X; Liu F; Shen S
Oncotarget; 2016 Jul; 7(29):45370-45384. PubMed ID: 27248318
[TBL] [Abstract][Full Text] [Related]
27. Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity.
Taki S; Matsuoka K; Nishinaga Y; Takahashi K; Yasui H; Koike C; Shimizu M; Sato M; Sato K
J Immunother Cancer; 2021 Oct; 9(11):. PubMed ID: 34725216
[TBL] [Abstract][Full Text] [Related]
28. Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments.
Du Y; Liang X; Li Y; Sun T; Xue H; Jin Z; Tian J
Cancer Lett; 2018 Feb; 414():230-238. PubMed ID: 29175457
[TBL] [Abstract][Full Text] [Related]
29. Near-infrared photoimmunotherapy of pancreatic cancer using an indocyanine green-labeled anti-tissue factor antibody.
Aung W; Tsuji AB; Sugyo A; Takashima H; Yasunaga M; Matsumura Y; Higashi T
World J Gastroenterol; 2018 Dec; 24(48):5491-5504. PubMed ID: 30622378
[TBL] [Abstract][Full Text] [Related]
30. Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer
Stutvoet TS; van der Veen EL; Kol A; Antunes IF; de Vries EFJ; Hospers GAP; de Vries EGE; de Jong S; Lub-de Hooge MN
J Nucl Med; 2020 Dec; 61(12):1839-1844. PubMed ID: 32358092
[No Abstract] [Full Text] [Related]
31. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
Sudoyo AW; Kurniawan AN; Kusumo GD; Putra TP; Rexana FA; Yunus M; Budiyati AD; Kurniawan D; Utama A; Utomo AR
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3421-3427. PubMed ID: 31759368
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer.
Heskamp S; Wierstra PJ; Molkenboer-Kuenen JDM; Sandker GW; Thordardottir S; Cany J; Olive D; Bussink J; Boerman OC; Dolstra H; Aarntzen EHJG; Hobo WA
Cancer Immunol Res; 2019 Jan; 7(1):150-161. PubMed ID: 30459153
[TBL] [Abstract][Full Text] [Related]
33. Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma.
Inoue S; Horiuchi Y; Setoyama Y; Takeuchi Y; Beck Y; Murakami T; Odaka A
J Surg Res; 2020 Sep; 253():201-213. PubMed ID: 32380346
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways.
Wei F; Zhang T; Deng SC; Wei JC; Yang P; Wang Q; Chen ZP; Li WL; Chen HC; Hu H; Cao J
Cancer Lett; 2019 May; 450():1-13. PubMed ID: 30776481
[TBL] [Abstract][Full Text] [Related]
35. A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody.
Lee EJ; Jang GY; Lee SE; Lee JW; Han HD; Park YM; Kang TH
Immunol Lett; 2021 Dec; 240():137-148. PubMed ID: 34710507
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
Lesniak WG; Chatterjee S; Gabrielson M; Lisok A; Wharram B; Pomper MG; Nimmagadda S
Bioconjug Chem; 2016 Sep; 27(9):2103-10. PubMed ID: 27458027
[TBL] [Abstract][Full Text] [Related]
37. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
[TBL] [Abstract][Full Text] [Related]
38. WTAP-induced N
Liu QZ; Zhang N; Chen JY; Zhou MJ; Zhou DH; Chen Z; Huang ZX; Xie YX; Qiao GL; Tu XH
Cancer Sci; 2024 Jun; 115(6):1749-1762. PubMed ID: 38508217
[TBL] [Abstract][Full Text] [Related]
39. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.
Tang H; Liang Y; Anders RA; Taube JM; Qiu X; Mulgaonkar A; Liu X; Harrington SM; Guo J; Xin Y; Xiong Y; Nham K; Silvers W; Hao G; Sun X; Chen M; Hannan R; Qiao J; Dong H; Peng H; Fu YX
J Clin Invest; 2018 Feb; 128(2):580-588. PubMed ID: 29337303
[TBL] [Abstract][Full Text] [Related]
40. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
